Virax Biolabs Group Limited(VRAX)

Biotechnology · Lanarkshire, SC

$2.03-0.37 (-15.42%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T20:48:44.253Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:48:44.253Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 378,849
Total debt · period ending 2026-03-31: 414,387
Cash · period ending 2026-03-31: 6,438,909
TTM revenue · period ending 2026-03-31: N/A

FMP input reference: 76ce780248c1f493ccbdb0751af92273333f1ee075484263629f1dd5eb2dbf7e

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

VRAX EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

VRAX Competitors' EV/Sales Ratio

VRAX

Virax Biolabs Group Limited

Current

Market Cap

$378849.00

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NIKI

Niki BioSolutions, Inc.

vs VRAX

Market Cap

$403887.00

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XRTX

XORTX Therapeutics Inc.

vs VRAX

Market Cap

$481786.00

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SPRC

SciSparc Ltd.

vs VRAX

Market Cap

$250443.00

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VIVS

VivoSim Labs, Inc.

vs VRAX

Market Cap

$518606.00

EV/Sales Ratio

N/A

TTM Avg

1.41x

3Y Avg

1.41x

5Y Avg

1.41x

HCWB

HCW Biologics Inc.

vs VRAX

Market Cap

$545796.00

EV/Sales Ratio

0.95x

TTM Avg

22.73x

3Y Avg

233.34x

5Y Avg

409.95x

SLXN

Silexion Therapeutics Ltd.

vs VRAX

Market Cap

$110112.00

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBM

Psyence Biomedical Ltd.

vs VRAX

Market Cap

$95475.00

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SXTC

China SXT Pharmaceuticals, Inc.

vs VRAX

Market Cap

$667469.00

EV/Sales Ratio

N/A

TTM Avg

18336.38x

3Y Avg

32990.15x

5Y Avg

90979.77x

PRFX

PRF Technologies Ltd.

vs VRAX

Market Cap

$70884.00

EV/Sales Ratio

N/A

TTM Avg

159.76x

3Y Avg

159.76x

5Y Avg

159.76x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Virax Biolabs Group Limited (VRAX)	$378849.00	N/A	N/A	N/A	N/A
Niki BioSolutions, Inc. (NIKI)vs ›	$403887.00	N/A	N/A	N/A	N/A
XORTX Therapeutics Inc. (XRTX)vs ›	$481786.00	N/A	N/A	N/A	N/A
SciSparc Ltd. (SPRC)vs ›	$250443.00	N/A	N/A	N/A	N/A
VivoSim Labs, Inc. (VIVS)vs ›	$518606.00	N/A	1.41x	1.41x	1.41x
HCW Biologics Inc. (HCWB)vs ›	$545796.00	0.95x	22.73x	233.34x	409.95x
Silexion Therapeutics Ltd. (SLXN)vs ›	$110112.00	N/A	N/A	N/A	N/A
Psyence Biomedical Ltd. (PBM)vs ›	$95475.00	N/A	N/A	N/A	N/A
China SXT Pharmaceuticals, Inc. (SXTC)vs ›	$667469.00	N/A	18336.38x	32990.15x	90979.77x
PRF Technologies Ltd. (PRFX)vs ›	$70884.00	N/A	159.76x	159.76x	159.76x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics